Compare Meta Platforms Inc (META) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Meta Platforms Inc trades at $579.66 (market cap $1.53T), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Meta Platforms Inc pays a 0.35% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Meta Platforms Inc nearer its low. Which is the better fit depends on your goals.
| META | XBI | |
|---|---|---|
Market Cap | $1.53T | — |
Volume | 24,093,972 | — |
Sector | Media | Broad Market / Factor |
52-Week High | $790.00 | $164.28 |
52-Week Low | $525.72 | $86.92 |
Enterprise Value | $1.55T | — |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $579.51, down 2.59% in 24 hours, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $200.97B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a legal ruling in Massachusetts regarding youth addiction lawsuits.
The outlook remains positive with a consensus price target of $761.95 and 79% buy ratings from analysts, driven by AI innovation and solid fundamentals. Risks include regulatory challenges and high capital expenditures, but earnings beats and institutional buying support long-term growth potential.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
